文献速递慢性肾脏病

慢性肾脏病成人的抗肥胖药物治疗

Anti-obesity pharmacotherapy in adults with chronic kidney disease.
PubMed 文献 · Kidney Int · 2023-11-04

肥胖是肾脏病发生和进展的主要风险因素,也是慢性肾脏病患者优化管理的重大障碍。本综述以肾脏为导向,评估当前和未来的成人抗肥胖药物治疗,探讨治疗目标、推测的作用机制,并提出值得在慢性肾脏病人群中进一步探索的重要科学问题。

要点

  • 肥胖是慢性肾脏病发生和进展的主要风险因素。
  • 新型抗肥胖药物更安全、耐受性更好且更有效。
  • 需在慢性肾脏病人群中进一步探索抗肥胖治疗的科学问题。

核心结论

  • 更安全、耐受性更好且更有效的抗肥胖治疗选项正在改变肥胖管理。

研究设计与样本

  • 综述,以肾脏为导向评估成人当前和未来的抗肥胖药物治疗。

主要发现

  • 过去的抗肥胖药物减重效果有限且存在安全性和耐受性风险。
  • 新型治疗选项更安全、耐受性更好且更有效。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Obesity is a leading risk factor for the development and progression of kidney disease and a major barrier to optimal management of patients with chronic kidney disease. While in the past anti-obesity drugs offered only modest weight loss efficacy in exchange for various safety and tolerability risks, a wave of safer, more tolerable, and more effective treatment options is transforming the management of obesity. This review evaluates current and future pharmacologic anti-obesity therapy in adults through a kidney-oriented lens. It also explores the goals of anti-obesity treatment, describes the underlying putative mechanisms of action, and raises important scientific questions that deserve further exploration in people with chronic kidney disease.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Taber-Hight E, Gilmore A, Friedman AN, et al. Anti-obesity pharmacotherapy in adults with chronic kidney disease. Kidney Int. 2023. PMID: 37926421. doi:10.1016/j.kint.2023.10.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。